Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Organigram Global Inc. is a leading Canadian cannabis company specializing in the production and sale of medical and recreational cannabis products. Founded in 2010 and headquartered in Toronto, it operates state-of-the-art cultivation and manufacturing facilities across Canada. Organigram’s diverse product portfolio includes whole flower, milled and pre-rolled cannabis, vapes, beverages, gummies, concentrates, and edible products under multiple well-known brands such as SHRED, Holy Mountain, Big Bag O’ Buds, and Edison Cannabis Co. The company utilizes advanced three-tier indoor cultivation technology to optimize quality and yield, alongside dedicated facilities for extraction and product manufacturing. Through innovation and a scientific approach, Organigram is committed to quality, sustainability, and expanding its global reach via strategic international partnerships. It serves both medical and adult-use markets, distributing products through wholesale, retail, and online channels. Organigram plays a significant role in shaping the evolving cannabis industry by driving product development, regulatory advocacy, and responsible cannabis consumption.
C$1.36
+C$0.01 (+0.74%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-5.90% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 62.2% YoY with margins expanding 16.4pp.
Negative free cash flow of -C$25M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$274M
▲ +62.2% YoY
Net Income (TTM)
-C$25M
▲ +45.5% YoY
Op. Margin
-5.15%
▲ +16.4pp YoY
ROIC
-3.62%
▲ +3.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$21M
▼ -1580.8% YoY
Op. Cash Flow (TTM)
C$39M
▼ -357.0% YoY
Net Debt
-C$20M
Net Cash Position
Cash & Equiv.
C$29M
3Y CAGR: +48.5%
Continue Research
Organigram Global (OGI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Organigram Global scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Organigram Global scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -5.2% operating margin and a -3.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OGI's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.